1National Institute for Health and Care Excellence. Depression: The NICE Guideline on the Treatment and Management of Depression in Adults (CG90). NICE, 2010.
2Spijker, J, Bockting, CLH, Meeuwissen, JAC, van Vliet, IM, Emmelkamp, PMG, Hermens, MLM, et al. Multidisciplinaire richtlijn Depressie (Derde revisie) : Richtlijn voor de diagnostiek, behandeling en begeleiding van volwassen patiënten met een depressieve stoornis. Trimbos-Instituut, 2013.
3American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. American Psychiatric Association, 2010.
4Undurraga, J, Baldessarini, RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012; 37: 851–64.
5Taylor, MJ, Freemantle, N, Geddes, JR, Bhagwagar, Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: a systematic review and meta-analysis. Arch Gen Psychiatry 2006; 63: 1217–23.
6Stassen, HH, Angst, J, Hell, D, Scharfetter, C, Szegedi, A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007; 68: 1195–205.
7Szegedi, A, Jansen, WT, Van Willigenburg, APP, Van Der Meulen, E, Stassen, HH, Thase, ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009; 70: 344–53.
8Uher, R, Mors, O, Rietschel, M, Rajewska-Rager, A, Petrovic, A, Zobel, A, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry 2011; 72: 1478–84.
9Gorwood, P, Bayle, F, Vaiva, G, Courtet, P, Corruble, E, Llorca, P-M. Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. Eur Psychiatry 2013; 28: 362–71.
10Wagner, S, Engel, A, Engelmann, J, Herzog, D, Dreimüller, N, Müller, MB, et al. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with major depressive disorder: systematic review and meta-analysis. J Psychiatr Res 2017; 94: 96–106.
11Fried, EI, Nesse, RM. Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. BMC Med 2015; 13: 72.
12Uher, R, Perlis, RH, Henigsberg, N, Zobel, A, Rietschel, M, Mors, O, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2012; 42: 967–80.
13Chekroud, AM, Zotti, RJ, Shehzad, Z, Gueorguieva, R, Johnson, MK, Trivedi, MH, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 2016; 3: 243–50.
14Tokuoka, H, Takahashi, H, Ozeki, A, Kuga, A, Yoshikawa, A, Tsuji, T, et al. Trajectories of depression symptom improvement and associated predictor analysis: an analysis of duloxetine in double-blind placebo-controlled trials. J Affect Disord 2016; 196: 171–80.
15Funaki, K, Nakajima, S, Suzuki, T, Mimura, M, Uchida, H. Early improvements in individual symptoms to predict later remission in major depressive disorder treated with mirtazapine. J Clin Pharmacol 2016; 56: 1111–9.
16Sakurai, H, Uchida, H, Abe, T, Nakajima, S, Suzuki, T, Pollock, BG, et al. Trajectories of individual symptoms in remitters versus non-remitters with depression. J Affect Disord 2013; 151: 506–13.
17Mizushima, J, Uchida, H, Tada, M, Suzuki, T, Mimura, M, Nio, S. Early improvement of specific symptoms predicts subsequent recovery in bipolar depression. J Clin Psychiatry 2017; 78: e146–51.
18Berlin, I, Lavergne, F. Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction. Eur Psychiatry 1998; 13: 138–42.
19Farabaugh, AH, Bitran, S, Witte, J, Alpert, J, Chuzi, S, Clain, AJ, et al. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol 2010; 25: 214–7.
21Leucht, S, Fennema, H, Engel, R, Kaspers-Janssen, M, Lepping, P, Szegedi, A. What does the HAMD mean? J Affect Disord 2013; 148: 243–8.
22Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391(10128): 1357–66.
23Tibshirani, R. Regression selection and shrinkage via the lasso. J R Stat Soc B 1996; 58: 267–88.
24Friedman, J, Hastie, T, Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010; 33: 1–22.
25Posternak, MA, Baer, L, Nierenberg, AA, Fava, M. Response rates to fluoxetine in subjects who initially show no improvement. J Clin Psychiatry 2011; 72: 949–54.
26Bschor, T, Kern, H, Henssler, J, Baethge, C. Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry 2018; 79(1): 16r10749.
27Ruhé, HG, Huyser, J, Swinkels, JA, Schene, AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder - systematic review. Br J Psychiatry 2006; 189: 309–16.
28Dold, M, Bartova, L, Rupprecht, R, Kasper, S. Dose escalation of antidepressants in unipolar depression: a meta-analysis of double-blind, randomized controlled trials. Psychother Psychosom 2017; 86: 283–91.
29Ueno, F, Nakajima, S, Suzuki, T, Abe, T, Sato, Y, Mimura, M, et al. Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression. J Clin Psychiatry 2015; 76: 434–9.
30Hieronymus, F, Nilsson, S, Eriksson, E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry 2016; 6: e834.
31Zhou, X, Ravindran A, V, Qin, B, Del Giovane, C, Li, Q, Bauer, M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression. J Clin Psychiatry 2015; 76: e487–98.
32Adli, M, Baethge, C, Heinz, A, Langlitz, N, Bauer, M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387–400.
33Jakubovski, E, Varigonda, AL, Freemantle, N, Taylor, MJ, Bloch, MH. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 2015; 54: 557–64.
34Wisniewski, SR, Rush, AJ, Nierenberg, AA, Gaynes, BN, Warden, D, Luther, JF, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009; 166: 599–607.
35Gullion, CM, Rush, AJ. Toward a generalizable model of symptoms in major depressive disorder. Biol Psychiatry 1998; 44: 959–72.
36Uher, R, Perlis, RH, Placentino, A, Dernovšek, MZ, Henigsberg, N, Mors, O, et al. Self-report and clinician-rated measures of depression severity: can one replace the other? Depress Anxiety 2012; 29: 1043–9.